Business
Firefly Neuroscience applies AI and electrophysiological data to help clinicians assess brain function through the Firefly Platform and Evoke System.
Firefly revenue rebounded to $1.14M, but net loss widened to $19.9M and forensic scores flagged stress.
The read at a glance✓ Audited against SEC data
- Business mix — AI precision neuroscience platformNote
- Revenue — Revenue rose to $1.14MOK
- Profitability — Net loss widened to $19.9MWatch
- Cash — Cash from ops was -$8.19MWatch
- Balance sheet — Equity improved to $7.64MOK
- Insiders — 0 buys / 10 sellsWatch
- Accounting — Altman-Z distress; Beneish flaggedWatch
Where the revenue comes from
Fiscal 2025, as FIREFLY NEUROSCIENCE, INC. reports it. History and quarterly detail are in the app.
- Service$814K
- Product$111K
- Subscription and Circulation$110K
- Rentals$74K
- Product and Service, Other$33K
Leadership changes
From FIREFLY NEUROSCIENCE, INC.'s own filings, the day they're filed.
- David DeCaprio · President · appointmenteff. 2025-04-18
- David DeCaprio · chairperson · departureeff. 2025-04-18
- Arun Menawat · chairperson · departureeff. 2025-04-18
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-07
- DEF 14A · Annual proxy (pay & governance)2026-07-09
- 8-K · Company announcement2026-06-26
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about FIREFLY NEUROSCIENCE, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.